Related Experiment Video
Updated: Apr 12, 2026
Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
Published on: April 2, 2017
Modulating G6PD/PGD to overcome FSP1/DHODH-mediated ferroptosis defence: A novel oridonin derivative suppresses liver
Chenhui Ma1,2,3, Li Han2,3, Hong Yao4
1Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo, China.
Background:
Hepatocellular carcinoma (HCC), a globally prevalent malignancy with high mortality rates, presents an unmet need for innovative effective therapies.
Purpose:
This study aimed to explore the antitumour potential of compound XD, a novel oridonin derivative, on HCC and its underlying mechanism.
Experimental Approach:
The antitumour effects of compound XD were investigated in several HCC cells lines and mice models. The mechanism of XD was investigated using FACS, qPCR, WB, ELISA, IHC, siRNA and plasmid transfection.
Key Results:
Compound XD demonstrated potent inhibitory effects, surpassing sorafenib with a maximum of 10-fold lower IC50 values against HCC cell lines. Its anticancer activities were ferroptosis dependent, which could be attenuated by ferroptosis inhibitors including deferoxamine, ferrostatin-1 and N-acetyl-cysteine. Unlike sorafenib, XD decreased two pivotal regulator FSP1 and DHODH to induce ferroptosis, while their overexpression partially mitigated XD-induced cytotoxicity and lipid peroxidation. In addition, XD treatment decreased cellular NADPH levels and inhibited the expression of G6PD and PGD in NADPH generation. Overexpression of G6PD or PGD reversed FSP1 and DHODH down-regulation, rescuing the ferroptosis induced by XD. Bioinformation analysis indicated the significant up-regulation of G6PD and PGD in clinical HCC patients and was positively correlated with cancer stages. Molecular docking and CETSA assay confirmed the binding capacity of XD with G6PD and PGD protein. Finally, XD dose-dependently inhibited liver tumour growth and induced ferroptosis-related markers in mice.
Conclusion And Implications:
This study suggests XD as a potential ferroptosis inducer and the potential role of G6PD/PGD/FSP1/DHODH axis in governing ferroptosis sensitivity in HCC.
Insights
Compound XD, a novel oridonin derivative, effectively inhibits hepatocellular carcinoma (HCC) by inducing ferroptosis. This new agent targets the G6PD/PGD/FSP1/DHODH axis, offering a promising therapeutic strategy for HCC.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Hepatocellular carcinoma (HCC) is a prevalent malignancy with high mortality.
- There is a critical need for novel and effective therapies for HCC.
Purpose of the Study:
- To investigate the anti-tumor potential of compound XD, a novel oridonin derivative, against HCC.
- To elucidate the underlying mechanism of action for compound XD in HCC.
Main Methods:
- In vitro studies using HCC cell lines and in vivo studies using mouse models.
- Mechanism investigation involved Flow Cytometry, qPCR, Western Blot, ELISA, IHC, siRNA, and plasmid transfection.
- Molecular docking and Cellular Thermal Shift Assay (CETSA) were used to confirm protein binding.
Main Results:
- Compound XD exhibited potent anti-HCC effects, with significantly lower IC50 values than sorafenib.
- XD-induced anti-cancer activity was dependent on ferroptosis, evidenced by attenuation with ferroptosis inhibitors.
- XD decreased G6PD, PGD, FSP1, and DHODH expression, key regulators of ferroptosis, and inhibited NADPH generation.
Conclusions:
- Compound XD acts as a potent ferroptosis inducer in HCC.
- The G6PD/PGD/FSP1/DHODH axis plays a crucial role in regulating ferroptosis sensitivity in HCC.
- XD demonstrates significant potential as a novel therapeutic agent for HCC.
More Related Videos
04:53Detection of Total Reactive Oxygen Species in Adherent Cells by 2',7'-Dichlorodihydrofluorescein Diacetate Staining
Published on: June 23, 2020
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
01:29Pharmacogenomics: Identification of New Drug Targets